Riccardi, Ferdinando |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
DUPLE, NCT06418087: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) |
|
|
| Recruiting | 2 | 49 | Europe | Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI], Carboplatino AHCL 10 mg/ml Concentrate for solution for infusion, Etoposide 20 mg/ml Concentrate for solution for infusion | Gruppo Oncologico Italiano di Ricerca Clinica | Pulmonary Large-cell Neuroendocrine Carcinoma | 12/26 | 12/26 | | |
GIM24-PALBO-BP, NCT04318223 / 2019-000221-45: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy |
|
|
| Recruiting | 2 | 168 | Europe | Palbociclib | Consorzio Oncotech | Metastatic Breast Cancer, Locally Advanced Breast Cancer | 07/23 | 07/23 | | |
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). |
|
|
| Not yet recruiting | 2 | 142 | Europe | Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide | Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 08/28 | 06/29 | | |
| Recruiting | N/A | 800 | Europe | Registration in a database | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Bone Metastases | 01/30 | 01/30 | | |
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments |
|
|
| Recruiting | N/A | 10000 | Europe | | Consorzio Oncotech | Metastatic Breast Cancer | 06/23 | 12/25 | | |
| Recruiting | N/A | 15000 | Europe | Data collection (retrospective), Data collection (prospective) | National Cancer Institute, Naples | Oncology | 01/25 | 07/26 | | |
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy |
|
|
| Recruiting | N/A | 300 | Europe | Trastuzumab emtansine | Consorzio Oncotech, Roche Pharma AG | Breast Cancer | 09/24 | 05/25 | | |
| Recruiting | N/A | 3600 | Europe | | Italian Association Neuroendocrine Tumors | Gastro-entero Pancreatic Neuroendocrine Tumors | 07/27 | 07/32 | | |